sitagliptin - Profile

What are the generic drug sources for sitagliptin and what is the scope of freedom to operate?

Sitagliptin is the generic ingredient in four branded drugs marketed by Zydus Lifesciences, Azurity, Merck Sharp Dohme, Apotex, Sandoz, and Watson Labs Inc, and is included in six NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Sitagliptin has four patent family members in four countries.

There are twenty-four tentative approvals for this compound.

Summary for sitagliptin

International Patents:	4
US Patents:	4
Tradenames:	4
Applicants:	6
NDAs:	6

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for sitagliptin

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Generic filers with tentative approvals for SITAGLIPTIN

Applicant	Application No.	Strength	Dosage Form
		50MG;1000MG	TABLET;ORAL
		50MG;500MG	TABLET;ORAL
		100MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

US Patents and Regulatory Information for sitagliptin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zydus Lifesciences	ZITUVIO	sitagliptin	TABLET;ORAL	211566-001	Oct 18, 2023		RX	Yes	No			Y
Zydus Lifesciences	ZITUVIO	sitagliptin	TABLET;ORAL	211566-002	Oct 18, 2023		RX	Yes	No			Y
Zydus Lifesciences	ZITUVIO	sitagliptin	TABLET;ORAL	211566-003	Oct 18, 2023		RX	Yes	Yes			Y

EU/EMA Drug Approvals for sitagliptin

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp & Dohme B.V.	Xelevia	sitagliptin	EMEA/H/C/000762For adult patients with type-2 diabetes mellitus, Xelevia is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination with:a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control;a PPARγ agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.Xelevia is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.	Authorised	no	no	no	2007-03-21
Merck Sharp & Dohme B.V.	Tesavel	sitagliptin	EMEA/H/C/000910For patients with type-2 diabetes mellitus, Tesavel is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a PPARγ agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination witha sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control;a peroxisome-proliferator-activated-receptor-gamma (PPARγ) agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control.Tesavel is also indicated as add on to insulin (with or without metformin) when diet and exercise plus stable dosage of insulin do not provide adequate glycaemic control.	Authorised	no	no	no	2008-01-10
Merck Sharp and Dohme B.V	Januvia	sitagliptin	EMEA/H/C/000722For adult patients with type-2 diabetes mellitus, Januvia is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a peroxisome-proliferator-activated-receptor-gamma (PPARγ) agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;a PPARγ agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination with:a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control;a PPARγ agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.Januvia is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.	Authorised	no	no	no	2007-03-20

International Patents for sitagliptin

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2015128877
South Africa	201606075	PHARMACEUTICAL COMPOSITIONS OF SITAGLIPTIN
India	651MU2014

Supplementary Protection Certificates for sitagliptin

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1412357	122007000056	Germany		PRODUCT NAME: SITAGLIPTIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE FUER SITAGLIPTINPHOSPHAT-MONOHYDRAT; REGISTRATION NO/DATE: EU/1/07/383/001-018 20070321
1412357	CA 2008 00035	Denmark		PRODUCT NAME: SITAGLIPTIN VALGFRIT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER MONOPHOSPHAT, METFORMIN VALGFRIT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER HYDROCHLORID
0896538	07C0035	France		PRODUCT NAME: SITAGLIPTIN; REGISTRATION NO/DATE IN FRANCE: EU/1/07/383/001 DU 20070321; REGISTRATION NO/DATE AT EEC: EU/1/07/383/001-018 DU 20070321

Sitagliptin: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

Sitagliptin, marketed as Januvia by Merck & Co., is a leading dipeptidyl peptidase-4 (DPP-4) inhibitor used for type 2 diabetes mellitus management. Since its approval in 2006 (FDA), sitagliptin has become a cornerstone in the oral antidiabetic market. Its strong patent protection, clinical efficacy, and safety profile have sustained its market dominance. However, recent patent expirations and the entry of biosimilars and alternative mechanisms threaten its long-term profitability. Analyzing its current market landscape, growth potential, and competitive pressures provides vital insights for investors and stakeholders.

---

Market Overview and Dynamics

Global Market Size and Forecast

Year	Market Size (USD Billion)	CAGR (2018–2028)	Notes
2022	$6.2	8.2%	Driven by rising diabetes prevalence in emerging markets
2028	$11.4	—	Projected based on current growth trends

Source: MarketResearchFuture (2023), IQVIA (2023)

Key Drivers

• Increasing global prevalence of type 2 diabetes, projected to reach 700 million cases worldwide by 2045.
• Growing acceptance of oral antidiabetics over injectable therapies.
• Expanding markets in Asia-Pacific, Latin America, and Africa due to urbanization and lifestyle changes.
• Evolving treatment guidelines favoring combination therapies, including DPP-4 inhibitors.

Key Challenges

• Patent expirations commencing in 2026.
• Competition from newer agents such as SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin).
• The advent of biosimilars and generics.
• Regulatory landscape differences impacting biosimilar approval.

---

Financial Trajectory and Investment Outlook

Revenue Analysis

Year	Revenue (USD Million)	Remarks
2022	$2,200	Peak revenue (pre-expiration phase)
2026	~$1,500 (est.)	Patent expiry impact begins
2030	~$800 (projected)	Significant decline post-patent expiry

Sources: Merck Annual Reports (2022), EvaluatePharma (2023)

Key Revenue Contributors

• Established markets (US, EU): Account for approximately 70% of sales.
• Emerging markets: Growing contribution, especially China, India, Brazil.
• Combination Thermapies: Increasing revenues via fixed-dose combinations (FDCs), e.g., sitagliptin + metformin.

Patent Timeline and Market Exclusivity

Patent Type	Expiration Year	Comments
Composition of matter patent	2026	Primary patent, offering market exclusivity
Method of use patent	2024–2025	Supplementary protection
Formulation patents	2026–2028	Extended protection with reformulations

Note: Post-2026, biosimilar entry and generic competition are expected to erode revenue significantly unless new formulations or indications are developed.

---

Market Share and Competitive Landscape

Company	Key Products	Market Share (2022)	Notes
Merck	Januvia, Janumet	~65%	Dominant due to early approval and brand loyalty
Novartis	Galvus	~12%	Significant but declining post patent expiration
AstraZeneca	Onglyza, Kombiglyze	~7%	Niche player, facing competition from newer agents
Others	Various generics and biosimilars	~16%	Entry of generics post-patent expiry

Note: The market share is highly concentrated; Merck’s Januvia remains the leading DPP-4 inhibitor.

Biosimilar and Generic Threats

• Biosimilars for sitagliptin are not yet approved in major markets but are under development.
• Generics expected post-2026, with competition likely leading to price erosion of 60-80%.

---

Market Drivers and Opportunities

Driver	Impact	Strategic Implications
Rising diabetes prevalence	Sustains long-term demand	Investments in new formulations, combination therapies
Patent cliff approaching	Revenue decline	Diversify portfolio with pipeline drugs or FDCs
Growing Asian markets	Expanding revenue streams	Local partnerships and manufacturing opportunities
Regulatory advancements	Faster pathway for biosimilars	Prepare for biosimilar registration and commercialization

Emerging Markets Focus

Region	CAGR (2022–2028)	Potential Growth Drivers
China	10%	Large patient base, government initiatives
India	9%	Rapid urbanization, healthcare infrastructure growth
Brazil	7%	Increasing diabetes therapy adoption

Note: Tailored strategies are crucial in these regions due to pricing, regulatory, and patent landscape differences.

---

Comparison with Competing Therapeutics

Therapy Class	Examples	Advantages	Challenges	Market Share (2022)
SGLT2 inhibitors	Jardiance, Invokana	Cardiovascular benefits	Cost, adverse effects	~15%
GLP-1 receptor agonists	Trulicity, Ozempic	Weight loss, robust glycemic control	Injectable route, cost	~10%
DPP-4 inhibitors	Sitagliptin, Vildagliptin	Oral administration, safety profile	Moderate efficacy	~65% (merck’s Januvia)

Financial Risks and Mitigation Strategies

Risk	Impact	Mitigation
Patent expiry	Revenue decline	Develop or acquire pipeline drugs; FDCs
Competition	Price erosion	Differentiate through formulations, indications
Regulatory delays	Market access issues	Engage early with authorities, invest in clinical trials

---

Conclusion: Investment and Strategic Outlook

Sitagliptin remains a lucrative asset for Merck, with robust current revenues bolstered by a dominant market share and diversified geographic presence. However, the approaching patent cliff, compounded by impending biosimilar entries, warrants proactive diversification strategies including pipeline expansion, formulation innovation, and entry into emerging markets.

Long-term profitability depends on successful navigation of biosimilar competition, expansion into new indications, and leveraging combination therapies. Investors should monitor patent statuses, regulatory environments, and market trends to optimize timing for divestment or reinvestment.

---

Key Takeaways

• Market Position: Sitagliptin is a leading DPP-4 inhibitor with approximately 65% market share in its class globally.
• Revenue Outlook: Expected to decline from ~$2.2 billion in 2022 to ~$800 million by 2030 post-patent expiry unless new revenue streams are developed.
• Patent Expiries: Primary patent protections to expire starting in 2026, opening markets to biosimilars and generics.
• Market Drivers: Increasing diabetes prevalence, rising demand in emerging markets, and combination therapy trends.
• Risks: Patent expiration, competitive erosion by novel agents (SGLT2, GLP-1), biosimilars, and regulatory delays.
• Opportunities: Portfolio diversification, FDCs, biosimilar development, and regional expansion.

---

FAQs

1. When will sitagliptin's patent protection expire?
   The primary composition of matter patent for sitagliptin is scheduled to expire in 2026, though secondary patents and formulations might extend exclusivity marginally.

2. What is the primary threat to sitagliptin’s market share?
   Biosimilar and generic entry post-2026, along with competition from newer classes like SGLT2 inhibitors and GLP-1 receptor agonists, threaten long-term dominance.

3. Are there new formulations or indications for sitagliptin in development?
   While no new approvals for sitagliptin are currently announced, development in fixed-dose combination products and potential new indications could provide revenue extension.

4. How can investors mitigate risks related to patent expiry?
   By diversifying portfolios to include pipeline candidates, investing in biosimilar development, and focusing on markets with limited generic penetration.

5. What are the key regulatory considerations for biosimilar entry?
   Approval pathways vary by region; the FDA and EMA have established biosimilar pathways that require comprehensive comparability data, often resulting in a 1–3 year approval timeline.

---

Sources:

[1] Merck & Co. Annual Report (2022)
[2] IQVIA (2023): Global Prescribed Drug Market Data
[3] MarketResearchFuture (2023): Diabetes Drugs Market Analysis
[4] EvaluatePharma (2023): Pharma Market Data
[5] U.S. FDA Approvals Database (2023)